Esperion Therapeutics (ESPR) Sees Strong Upside on Volume

September 20, 2016 11:44 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Esperion Therapeutics (NASDAQ: ESPR) is seeing sharp upside on heavy volume. Shares are up 16.5% on volume that is 6x normal. Upside could be coming amid M&A activity/valuation in the biotech space, including today's Allergan plc (NYSE: AGN) deal for Tobira Therapeutics, Inc. (NASDAQ: TBRA) at premium of up to 1650%.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Momentum Movers, Trader Talk

Add Your Comment